Title |
Therapeutic response and side effects of repeated radioligand therapy with 177 Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
|
---|---|
Published in |
Oncotarget, February 2016
|
DOI | 10.18632/oncotarget.7245 |
Pubmed ID | |
Authors |
Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer, Markus Essler |
Abstract |
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Canada | 1 | <1% |
Unknown | 151 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 14% |
Student > Ph. D. Student | 19 | 12% |
Student > Master | 18 | 12% |
Student > Doctoral Student | 13 | 8% |
Other | 12 | 8% |
Other | 31 | 20% |
Unknown | 38 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 54 | 35% |
Pharmacology, Toxicology and Pharmaceutical Science | 14 | 9% |
Chemistry | 14 | 9% |
Agricultural and Biological Sciences | 6 | 4% |
Engineering | 5 | 3% |
Other | 18 | 12% |
Unknown | 42 | 27% |